CTLA4 and neoplasm: For instance, combination therapies using LIGHT agonists with anti-PD-1 or anti-CTLA-4 antibodies have shown enhanced tumor clearance in preclinical models by reinvigorating exhausted T cells and promoting durable anti-tumor immunity (61, 62).